Blood Clotting and COVID 19 Vaccine
After conducting an updated analysis, evaluation and investigation of reported cases, the FDA has determined that the risk of thrombosis with thrombocytopenia syndrome (TTS), a syndrome of rare and potentially life-threatening blood clots in combination with low levels of blood platelets with onset of symptoms approximately one to two weeks following administration of the Janssen COVID-19 Vaccine, warrants limiting the authorized use of the vaccine. https://web.archive.org/web/20220505210145/https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-limits-use-janssen-covid-19-vaccine-certain-individuals In May 2022, the Food and Drug Administration (FDA) limited the authorized use of the Johnson & Johnson (J&J;) COVID-19 vaccine due to reports of a blood-clotting disorder https://web.archive.org/web/20221002141653/https://www.healthline.com/health/covid-vaccine-pulmonary-embolism